• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

采用甲泼尼龙、巴瑞替尼和瑞德西韦成功治疗1例合并帕博利珠单抗诱导性关节炎的肺癌患者的重症新型冠状病毒肺炎。

Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.

作者信息

Oda Naohiro, Miyoshi Keiji, Morichika Daisuke, Beika Yuka, Taki Takahiro, Mitani Reo, Okada Toshiaki, Takata Ichiro

机构信息

Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.

Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.

出版信息

Clin Case Rep. 2021 Jul 6;9(7):e04459. doi: 10.1002/ccr3.4459. eCollection 2021 Jul.

DOI:10.1002/ccr3.4459
PMID:34257986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8259795/
Abstract

COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.

摘要

正在使用免疫抑制剂治疗免疫检查点抑制剂免疫相关不良事件的癌症患者感染新型冠状病毒肺炎（COVID-19）后病情可能迅速恶化。甲泼尼龙、巴瑞替尼和瑞德西韦联合治疗对于重症COVID-19可能有效，有必要开展进一步的临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/476ec8b2ead8/CCR3-9-e04459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/d2401828dfa4/CCR3-9-e04459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/441cdfeec76b/CCR3-9-e04459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/476ec8b2ead8/CCR3-9-e04459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/d2401828dfa4/CCR3-9-e04459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/441cdfeec76b/CCR3-9-e04459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c1/8259795/476ec8b2ead8/CCR3-9-e04459-g003.jpg

相似文献

1
Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.采用甲泼尼龙、巴瑞替尼和瑞德西韦成功治疗1例合并帕博利珠单抗诱导性关节炎的肺癌患者的重症新型冠状病毒肺炎。
Clin Case Rep. 2021 Jul 6;9(7):e04459. doi: 10.1002/ccr3.4459. eCollection 2021 Jul.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.妥协还是不妥协？低剂量甲基强的松龙和双环醇成功治疗非小细胞肺癌患者因帕利珠单抗引起的肝炎 1 例报告。
Thorac Cancer. 2020 Jul;11(7):2023-2030. doi: 10.1111/1759-7714.13463. Epub 2020 May 7.
4
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.巴瑞替尼、瑞德西韦和地塞米松联合治疗 COVID-19 缺氧成人患者的疗效：一项回顾性研究。
Respir Med Res. 2022 May;81:100903. doi: 10.1016/j.resmer.2022.100903. Epub 2022 Mar 19.
5
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19.中度至重度新型冠状病毒肺炎紧急使用授权药物的药理学与不良事件
Pharmaceuticals (Basel). 2021 Sep 23;14(10):955. doi: 10.3390/ph14100955.
6
COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report.使用瑞德西韦、地塞米松和巴瑞替尼治疗的 COVID-19 相关肺曲霉病：一例报告
Cureus. 2022 Apr 2;14(4):e23755. doi: 10.7759/cureus.23755. eCollection 2022 Apr.
7
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.
8
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.瑞德西韦及其与再利用药物的联合应用作为 COVID-19 治疗药物。
Front Immunol. 2022 May 12;13:830990. doi: 10.3389/fimmu.2022.830990. eCollection 2022.
9
[Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].[皮质类固醇和免疫球蛋白联合成功治疗派姆单抗引起的吉兰-巴雷综合征样急性炎症性脱髓鞘性多发性神经病：病例报告]
Rinsho Shinkeigaku. 2020 Nov 27;60(11):773-777. doi: 10.5692/clinicalneurol.cn-001444. Epub 2020 Oct 27.
10
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.巴瑞替尼、瑞德西韦和地塞米松联合治疗重症 COVID-19 患者的临床影响。
Respir Investig. 2021 Nov;59(6):799-803. doi: 10.1016/j.resinv.2021.07.004. Epub 2021 Aug 10.

引用本文的文献

1
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review.JAK-STAT通路作为免疫检查点抑制剂诱导的结肠炎癌症患者的治疗策略：一项叙述性综述。
Cancers (Basel). 2024 Jan 31;16(3):611. doi: 10.3390/cancers16030611.
2
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.巴瑞替尼联合治疗：对严重 SARS-CoV-2 感染的重新定位 Janus 激酶抑制剂的叙述性综述。
Infection. 2022 Apr;50(2):295-308. doi: 10.1007/s15010-021-01730-6. Epub 2021 Dec 13.

本文引用的文献

1
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
2
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.COVID-19 对癌症免疫治疗相关风湿并发症患者的影响：一项注册调查研究结果。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001550.
3
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
巴瑞替尼改善了 COVID-19 肺炎患者接受皮质类固醇治疗后的呼吸功能：一项观察性队列研究。
Rheumatology (Oxford). 2021 Jan 5;60(1):399-407. doi: 10.1093/rheumatology/keaa587.
4
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?癌症免疫治疗相关免疫检查点抑制剂所致风湿免疫相关不良事件的治疗：是否到了范式转变的时候？
Clin Rheumatol. 2021 May;40(5):1687-1695. doi: 10.1007/s10067-020-05420-w. Epub 2020 Sep 28.
5
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.静脉注射甲泼尼龙脉冲治疗住院的严重 COVID-19 患者：一项随机对照临床试验的结果。
Eur Respir J. 2020 Dec 24;56(6). doi: 10.1183/13993003.02808-2020. Print 2020 Dec.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management.COVID-19 肺炎与免疫相关肺炎：鉴别诊断、潜在相互作用及处理的关键问题。
Expert Opin Biol Ther. 2020 Sep;20(9):959-964. doi: 10.1080/14712598.2020.1789097. Epub 2020 Jul 2.
8
Determinants of COVID-19 disease severity in patients with cancer.癌症患者 COVID-19 疾病严重程度的决定因素。
Nat Med. 2020 Aug;26(8):1218-1223. doi: 10.1038/s41591-020-0979-0. Epub 2020 Jun 24.
9
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.胸恶性肿瘤患者的 COVID-19（TERAVOLT）：一项国际、基于登记的队列研究的初步结果。
Lancet Oncol. 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4. Epub 2020 Jun 12.
10
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.PD-1 阻断对肺癌患者 COVID-19 严重程度的影响。
Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12.